Molecular Imaging

NYC researchers propose criteria for FMISO-PET imaging
By Will Morton
Proposed criteria for F-18 fluoromisonidazole (FMISO) PET imaging can help clinicians manage patients with head and neck cancer.
September 17, 2024
A graphical abstract of the study. Image courtesy of the Journal of Nuclear Medicine.
Radiotracer for kidney cancer performs well in phase III trial
By Will Morton
A PET radiotracer that detects clear-cell renal cell carcinoma proved safe and highly effective in a clinical trial conducted at 36 research hospitals across nine countries.
September 12, 2024
Pet Renal Cancer 66e1e00428375 Thumbnail
Cardiac PET use increases in coronary artery disease
By Will Morton
PET, CT, and MRI use for assessing coronary artery disease increased in Medicare patients from 2018 to 2022.
September 11, 2024
Heart 1
AI may help visualize cardiac sarcoidosis
By Will Morton
A deep-learning AI model shows promise in helping clinicians assess cardiac sarcoidosis on PET scans.
September 9, 2024
Examples of the standard myocardial perfusion imaging (MPI) segmentation, DL segmentation, and manual segmentation for negative (a) and positive (b) FDG-PET studies. Image courtesy of the American Society of Nuclear Cardiology.
PET tracer reveals treatment responses in cardiac amyloidosis patients
By Will Morton
PET/CT imaging with iodine-124 evuzamitide may help monitor how patients with cardiac amyloidosis respond to therapy over time.
September 6, 2024
I-124 evuzamitide PET/CT images of a patient with light-chain amyloidosis showing a decrease in amyloid load and organ volume on follow-up.
F-18 FAPI PET/CT upstages more newly-diagnosed breast cancers
By Amerigo Allegretto
F-18 FAPI PET/CT leads to significant upstaging in newly diagnosed breast cancer compared with F-18 FDG.
September 6, 2024
Breast Cancer Cell2 Social
Low risk of oropharynx cancer on PET/CT, surgeons advise
By Will Morton
Radiologists can help reduce unnecessary follow-up work in patients with suspected oropharynx cancer by analyzing certain metrics on PET/CT scans.
August 30, 2024
Headandneck2
PET reveals brain pathology that may drive depression
By Will Morton
Early brain accumulation of amyloid plaque on PET scans is associated with emerging depressive symptoms in cognitively unimpaired older adults.
August 29, 2024
Pittsburgh Compound B (PiB) PET distribution volume ratio (DVR) images were projected onto fsaverage surfaces from FreeSurfer and surface smoothed, with PiB (amyloid) slope maps created using ordinary least squares regression (time as only factor) and mixed effects models for 154 participants run at each vertex (P < .01; model: longitudinal Geriatric Depression Scale score estimated by amyloid slope × time + [sex + education + age] × time). This map visualizes the results of the linear mixed-effects models (t score of the main variable, amyloid slope × time) such that regions with a greater t score (red) represent areas in which greater depressive symptoms are associated with greater amyloid accumulation (amyloid slope). Anatomical landmarks are provided: L refers to the left hemisphere, R refers to the right hemisphere, and additional labels indicate the anterior and posterior ends of the brain. Images available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of JAMA Open Network.
PET/MRI shows promise in patients with large vessel vasculitis
By Will Morton
PET/MRI could be an invaluable tool for evaluating how patients with large vessel vasculitis respond to treatments, suggests a research team in Scotland.
August 27, 2024
2024 08 25 Natcomms Pet Mri Treatment Response Lvv Pugh Thumbnail
Micro-SPECT shows microplastics cause renal failure in mice
By Will Morton
Molecular imaging in mice has shown for the first time that environmental pollutants such as polyethylene microplastic could be a risk factor for kidney dysfunction.
August 23, 2024
A micro-SPECT image of a mouse treated with polyethylene microplastic showing decreased uptake of TC-99m DMSA radiotracer.
PET scans predict patient response to Pluvicto
By Will Morton
PET scans that determine whether men with prostate cancer are eligible for Pluvicto treatment can provide additional clues on how they may respond to the drug.
August 20, 2024
Whole-body anterior coronal PSMA-PET maximum intensity projection images in a 63-year-old white male participant with tumors in the liver, bone, and lymph node (LN) who had an initial prostate-specific antigen level of 181.9 ng/mL and Eastern Cooperative Oncology Group performance score of 0/1. The images show all PSMA-positive (PSMA+) disease as a single whole-body volume in red (left) and segmented according to anatomic region (right; bone lesions in blue, liver lesions in green, lymph node lesions in red).
FDG-PET scans can help predict risk of dementia
By Will Morton
A normal brain F-18 FDG-PET scan can rule out the short-term risk of dementia in older patients who present with cognitive complaints.
August 16, 2024
2024 08 13 Alztherapy Fdg Pet Rules Out Ad Heyer Image
Page 1 of 596
Next Page